Abstract-Neuropeptide Y (NPY) is implicated in the regulation of blood pressure (BP), and NPY pathways in the hypothalamus are sensitive to dietary fat. We evaluated the potential effect of a functional variant rs16147 located in the NPY gene pro moter region on the association between 2-year diet intervention and change in multiple BP measures in the randomized Preventing Overweight Using Novel Dietary Strategies Trial. The NPY rs16147 was genotyped in 723 obese adults who were randomly assigned to 1 of 4 diets differing in the target percentages of energy derived from fat, protein, and carbohydrate. The changes of 4 BP phenotypes, including systolic BP, diastolic BP, pulse pressure, and mean arterial pressure, during 2-year diet intervention were analyzed. In the total participants and participants with hypertension, we observed significant and consistent interactions between rs16147 genotype and dietary fat intake on changes in multiple BP phenotypes at 2 years (all P for interactions <0.05). The risk allele (C allele) was associated with a greater reduction of BP phenotypes in response to low-fat diet, whereas an opposite genetic effect was observed in response to high-fat diet. In addition, the C allele was related to greater changes in 4 BP phenotypes in hypertensive compared with nonhypertensive participants. Our data suggest that NPY rs16147 may modulate the association between dietary fat intake and changes in BP phenotypes, and the C allele exerts a long-term beneficial effect on lowering BP in response to low-fat diet in obese and hypertensive subjects. 
O besity frequently coexists with hypertension, and both are important risk factors for cardiovascular disease. 1 Many studies have shown that dietary intervention on weight loss resulted in lower blood pressure (BP), [2] [3] [4] and weight reduction is recommended in major guidelines as primary intervention in the treatment of high BP. 5 However, the BP-lowering effect with weight-loss response to dietary intervention exhibited substantial interindividual variations, 3, 6 and accumulating evidence suggests that genetic variants may contribute to such differential responses. [7] [8] [9] Neuropeptide Y gene (NPY) is widely expressed in the peripheral and central nervous systems 10 and is involved in diverse physiological functions, including BP regulation. [11] [12] [13] Previous studies showed that plasma NPY levels correlated with the BP levels 14 and were elevated in hypertensive patients. 15 In addition, NPY levels are modulated by dietary factors, especially dietary fat. [16] [17] [18] Recently, a functional single nucleotide polymorphism (SNP) in the promoter region of NPY, rs16147 (C-399T), was found to be related to risks for early onset atherosclerosis 19 and ischemic stroke 20 and showed allele-specific effects on NPY gene expression and NPY peptide level. 19, 21 However, no study has examined the effect of this functional genotype and its interaction with dietary factors on BP.
In this study, we aimed to investigate whether NPY rs16147 genotype modulated the effects of weight-loss diet varying in macronutrients on changes of BP phenotypes in a 2-year randomized intervention trial. In addition to systolic BP (SBP) and diastolic BP (DBP), we also assessed pulse pressure (PP, the difference between SBP and DBP), a measure of central arterial stiffness and a predictor of cardiovascular mortality, and mean arterial pressure (MAP), a weighted average of SBP and DBP. Both PP and MAP are predictive of hypertension and cardiovascular disease.
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Methods
Study Population
The The design and sample collection have been described previously in detail. 24 Briefly, the study population was composed of 811 overweight or obese participants aged 30 to 70 years and had a body mass index of 25 to 40 kg/m 2 . Major criteria for exclusion were the presence of diabetes mellitus treated with oral medications or insulin, or unstable cardiovascular disease, the use of medications that affect weight, and insufficient motivation as assessed by interview and questionnaire. Individuals with type 2 diabetes mellitus controlled by diet or with hypertension or hyperlipidemia treated with diet or drugs were eligible to participate. The participants were randomly assigned to 1 of 4 diets constituting a 2-by-2 factorial design; the target percentages of energy derived from fat, protein, and carbohydrate in the 4 diets were 20%, 15%, and 65%; 20%, 25%, and 55%; 40%, 15%, and 45%; and 40%, 25% and 35%. After 2 years, 645 participants (80% of total population) completed the trial. The study was approved by the human subjects committee and by a data and safety monitoring board appointed by the National Heart, Lung, and Blood Institute. All participants provided written informed consent.
Measurements
Body weight and waist circumference were measured in the morning before breakfast on 2 nonconsecutive days at baseline and at 6 and 24 months, as well as on a single day at 12 and 18 months. Dietary intake was assessed in a random sample of 50% of the participants by a review of the 5-day diet record at baseline and by 24-hour recall during a telephone interview on 3 nonconsecutive days at 6 months and 2 years. 24 Biomarkers of nutrient intake were used to validate selfreported adherence to macronutrient targets as follows: high-density lipoprotein cholesterol for carbohydrate, urinary nitrogen excretion for protein, and respiratory quotient for fat. 24, 25 Blood pressure was measured on 2 days at baseline and at 6, 12, and 24 months by an automated device (Omron HealthCare, HEM907XL). The calibration was evaluated at regular intervals using a mercury manometer. PP was calculated as SBP minus DBP, and MAP was determined using the following formula: 1/3 SBP+2/3 DBP.
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Genotyping DNA was extracted from the buffy coat fraction of centrifuged blood using the QIAmp Blood kit (Qiagen, Chatsworth, CA). SNP NPY rs16147 was genotyped successfully in 723 total participants with available DNA samples using the OpenArray SNP Genotyping System (BioTrove, Woburn, MA). The genotype success rate was 99%. Replicated quality control samples (10%) were included in every genotyping plate with >99% concordance.
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Statistical Analysis
The primary outcomes were changes in 4 BP phenotypes, including SBP, DBP, PP, and MAP, during the intervention. Because previous studies have shown that NPY was sensitive to dietary fat, [16] [17] [18] we, therefore, compared low-fat (20%) versus high-fat (40%) diets in the primary analysis and compared average-protein (15%) versus high-protein (25%) diets in the secondary analysis. We also performed stratified analysis according to baseline hypertension status. The Hardy-Weinberg equilibrium and comparison of categorical variables were assessed with χ 2 test. Differences in continuous variables at baseline were tested using general linear models, with adjustment for age, sex, and ethnicity. The main effects of genotype and genotype-diet interactions on changes of BP were analyzed using general linear models, adjusted for age, sex, ethnicity, baseline body mass index, baseline value for respective BP phenotypes, antihypertensive medication use, and weight loss. We excluded individuals with missing measures at each time point in the analysis. Linear mixed models, using time as a repeated measurement factor, were used to test genetic associations with the trajectory of changes in outcomes according to diet intervention during the 2 years of follow-up by including genotype-time interaction terms. Additive genetic models were analyzed for genotype, following the previous reports. 27, 28 Because the majority of the study population were white (80%), similar analyses were repeated in white participants. 
Results
Characteristics of Study Population
The distribution of NPY rs16147 genotype was in HardyWeinberg equilibrium in the study sample and the different ethnic groups (P>0.10), and the minor allele frequency was 0.48 in total participants. The genotype frequencies were significantly different among ethnicity (P=0.005). No significant differences across the genotype were observed in weight, body mass index, any of the BP phenotypes, the prevalence of hypertension, and biomarkers of adherence (urinary nitrogen, respiratory quotient, and high-density lipoprotein cholesterol) at baseline, although the genotype was related to age (Table) .
Effect of NPY rs16147 Genotype on 2-Year Changes in BP Response to Dietary Fat
In all the participants, statistically significant and consistent interactions between rs16147 genotype and dietary fat intake were found on changes in SBP, DBP, PP, and MAP during 2-year intervention after adjustment for potential confounders (P for interactions=0.0002, 0.014, 0.001, and 0.001, respectively) ( Figure 1 ). In the adjusted model, the C allele was associated with a greater decrease in 2 BP phenotype (SBP and MAP) responses to low-fat diet intake and an increase in 3 BP phenotype (SBP, PP, and MAP) responses to high-fat diet (all P<0.05) ( Figure 1 ). We next performed secondary analysis to test whether NPY rs16147 had different modulation on BP response to dietary fat intake in subgroups with (n=264) and without hypertension (n=459). In participants with hypertension, we observed significant gene-diet interactions on SBP, PP, and MAP using the same statistical models (P for interactions=0.0006, 0.0005, and 0.014, respectively) ( Figure 2 ). In the low-fat group, the risk allele (C allele) was associated with greater reduction in 3 BP phenotypes (SBP, PP, and MAP). Conversely, the C allele was associated with an increase in 2 BP phenotypes (SBP and PP) in the highfat group. In the nonhypertensive subjects, we did not find any significant interactions between rs16147 genotype and dietary fat intake and genetic effects on any of the BP phenotypes (all P>0.05). In addition, the C allele had greater changes in the 4 BP traits in hypertension compared with nonhypertension in response to both low-fat diet and high-fat diet (Table S1 in the online-only Data Supplement). When consuming low-fat diets, the C allele was associated with a 5.1-mm Hg greater reduction of SBP in subjects with hypertension but only with a 0.2-mm Hg greater reduction of SBP in nonhypertensive subjects. Similarly, less reduction of DBP, PP, and MAP was found in nonhypertensive subjects compared with hypertensive subjects.
At 2 years, no significant genetic effects and interactions were observed on changes in body weight (all P>0.05; Table S1 and Figure S1 in the online-only Data Supplement).
We did not find significant interactions between this NPY variant and dietary protein intake. Similar results were found when the analyses were restricted to the white participants.
Trajectory of Changes in BP Phenotypes by the NPY rs16147 Genotype in Response to Dietary Fat
We further examined the dynamic pattern of changes in BP phenotypes by NPY genotype during the 2-year intervention. In all the participants, we observed significant genotype-time interactions on changes in SBP and MAP response to low-fat diet (P for interactions=0.035 and 0.032) and changes in SBP and PP response to high-fat diet (P for interactions=0.027 and 0.034) (Figure 3 ). In the participants with hypertension, we observed significant and consistent genotype-time interactions on changes in all the 4 BP phenotypes in the low-fat group (P for interactions=0.003, 0.013, 0.026, and 0.004, respectively) but not in the high-fat group (Figure 4 ). In addition, in the low-fat group, the C allele was associated with sustained improvement in 2 BP phenotypes (SBP and MAP) in all the participants and 4 BP phenotypes in the participants with hypertension across 2-year intervention (Figures 3 and 4) . Consistent with the findings presented above, the genotype-time interactions on changes in BP were not significant in the nonhypertensive subjects. No significant genotype-time interaction on weight change in each subgroup was found over time ( Figure S2 ). The similar dynamic patterns of the genotype effects on BP phenotypes were observed in the white population.
Discussion
In the 2-year randomized weight-loss intervention trial, we observed significant and consistent interactions between the NPY rs16147 SNP and dietary fat intake in relation to changes in multiple BP phenotypes. Interestingly, such gene-diet interactions only appeared in hypertensive patients but not in nonhypertensive subjects. Carriers of the C allele exhibited significantly greater reduction in BP phenotypes when consuming low-fat diet but showed greater increase in BP phenotypes in response to high-fat diet intake at 2 years.
To the best of our knowledge, this is the first study examining the interactions between NPY genetic variant and dietary fat intake in relation to long-term changes of BP phenotypes. Our findings are in concordance with the functional roles of NPY in the regulation of BP. 11, 29 The SNP rs16147 (C-485T) is a functional variant located in the NPY gene promoter region and in linkage disequilibrium with other NPY SNPs, which were associated with early onset coronary artery disease in a previous study. 19 Consistent evidence has shown an allele-specific effect of rs16147 on NPY expression, and the SNP accounts for the majority of the variation in expression in vivo, 21, 30 which correlated with plasma NPY peptide levels. 21 The NPY SNP has been previously related to several BP-related conditions, such as early onset atherosclerosis 19 and ischemic stroke. 20, 31 Findings from the present study provide further support the significant association between the NPY genetic variant and BP regulation. Therefore, we can speculate that rs16147 polymorphism might affect the transcription efficiency and expression of NPY gene, resulting in changes either in systemic or in local levels of NPY, which can induce vasoconstriction and stimulate vascular smooth muscle cell proliferation and angiogenesis, as well as stimulate sympathetic nervous system activity, contributing to an increase in BP level. 29, 32 Several previous studies have demonstrated that NPY pathways in the hypothalamus were responsive to the amounts of fat present in the ingested diet. 33, 34 In animal studies, longterm feeding of high-fat diets led to decreased NPY levels in hypothalamus, 16, 17 whereas feeding of low-fat diets led to an increased NPY gene expression in hypothalamus. 18 These studies provide fundamental evidence for the potential mechanisms underlying the observed gene-dietary fat interaction in relation to changes in BP. Our results showed that carriers of the C allele exhibited opposite effects on BP changes in response to low-and high-dietary fat intakes, which are in line with a recently proposed hypothesis of differential susceptibility. The hypothesis suggests that vulnerability genes or risk alleles may function more like plasticity genes, thereby rendering some individuals more responsive to environmental influences than others where genetic risk is either attenuated by a favorable environment or amplified by an adverse environment. 18, 33 Consistent with this idea, our data supported that the risk allele (C allele) may act as either a protective or a detrimental factor, depending on the differential exposure to dietary fat intake.
Another intriguing finding from the present study is that the gene-diet interaction was only observed in participants with hypertension, and the risk allele had remarkably greater changes in 4 BP phenotypes in hypertensive patients than those without hypertension in response to low-fat or high-fat diet interventions. The results suggest that the initial BP levels might affect the NPY genetic modulation on subsequent BP changes by a diet intervention. These findings indicate that lowfat diets might benefit more on those with the C allele and high BP. In contrast, when consuming a high-fat diet, carriers of the C allele with hypertension had a more unfavorable effect on BP.
There are several potential limitations that warrant consideration. First, we only analyzed 1 SNP, rs16147. However, this SNP is a functional variant with high frequency and in linkage disequilibrium with several previously reported variants related to cardiovascular disease. 19 Our sample size rendered us insufficient power to test gene-diet interactions for rare variants. Thus, we did not include low-frequency SNPs such as rs16139, which has also been previously reported. 35 In addition, although our study is thus far the largest and longest diet intervention trial on changes in BP, the size may be relatively small to detect small genetic effects or gene-diet interactions. Furthermore, it is difficult to tease out which macronutrient is responsible for the observed interactions because diet fat is correlated with other macronutrients, such as carbohydrates. Finally, because the majority of the participants in the present study are whites and of a specific body mass index range, the generalizability of our findings to other minority groups or the general population with normal range of body weight needs to be further verified.
In conclusion, we found that genetic variation within the NPY promoter region might modulate long-term changes of BP in response to weight-loss diet intervention varying in fat among overweight or obese subjects. Individuals with the C allele showed a greater reduction in BP in response to lowfat diet but more increase in BP in response to high-fat diet, and such interactions only presented in hypertensive subjects. These findings may provide novel information on the development of effective diet intervention in lowering BP levels in high-risk populations.
Perspectives
NPY is implicated in the regulation of BP, and NPY pathways in the hypothalamus are sensitive to dietary fat. A functional variant rs16147 located in the promoter region of NPY gene was found to influence NPY gene expression, NPY levels, BP, and cardiovascular risk. We evaluated the potential effect of variant rs16147 on the association between 2-year weight-loss diet intervention and changes in multiple BP measures in 723 obese patients from the randomized Pounds Lost Trial. Our results indicate that individuals with the C allele (the risk allele for high BP) might significantly benefit from low-fat diet intake in long-term reduction of BP phenotypes, and such benefits were more evident in hypertensive subjects. These findings may provide novel information for the development of a personalized, more effective diet intervention based on genetic background in the prevention of hypertension. 
